Zacks Bull and Bear of the Day Highlights: Tyson Foods, Goldcorp, Novo Nordisk, Sanofi and Bayer

    Zacks Bull and Bear of the Day Highlights: Tyson Foods, Goldcorp, Novo
                          Nordisk, Sanofi and Bayer

PR Newswire

CHICAGO, Feb. 12, 2013

CHICAGO, Feb. 12, 2013 /PRNewswire/ --Zacks Equity Research highlights Tyson
Foods (NYSE:TSN) as the Bull of the Day and Goldcorp (NYSE:GG) as the Bear of
the Day. In addition, Zacks Equity Research provides analysis on Novo Nordisk
(NYSE:NVO), Sanofi (NYSE:SNY) and Bayer AG (OTC:BAYRY).


Full analysis of all these stocks is available at

Here is a synopsis of all five stocks:

Bull of the Day:

With the economy seemingly back on track, many investors have looked to higher
beta stocks. However, there are also plenty of firms in corners like the
consumer staples market which could still be great bets during this

One such company is Tyson Foods (NYSE:TSN), the world's largest
fully-integrated producer, processor, and marketer of chicken and
poultry-based food products. This firm may have been overlooked in the recent
market surge, but recent trends suggest that it could still have plenty of
room to run, while still being a lower risk stock.

TSN has seen a big move higher in terms of analyst expectations over the past
few weeks. With nine estimates on the company, six have moved higher in the
past week for both the current quarter, and the current fiscal year periods.

If that wasn't enough, the magnitude of these revisions has also been
enormous. Current quarter estimates have jumped from 30 cents a share to 46
cents a share in the past 90 days, while full year estimates have leaped from
$1.59 a share to $2.02 for the same time period.

Bear of the Day:

While gold has broadly outperformed stocks over the past few years, this has
pretty much reversed in the past few months. Now, safety oriented precious
metals are slumping while stocks are marching towards fresh all-time highs.

This trend has led many to abandon gold for the time being as its traditional
role as a store of value and inflation hedge isn't in demand in these types of
markets. Gold's lack of appeal could continue now that China and other
emerging markets are back on track, while Europe's debt issues have subsided
for the time being.

While this has had a negative impact on gold prices, it has been even worse
news for gold miners. That is because these often trade as a leveraged play on
precious metal prices, so they can often underperform spot prices when metals
are slumping.

In particular, this situation has been especially bad news for Goldcorp
(NYSE:GG), a firm that could continue to see weakness if current conditions

Latest Posts on the Zacks Analyst Blog:

Novo Nordisk Suffers Setback

Novo Nordisk (NYSE:NVO) recently faced a setback when the US Food and Drug
Administration (FDA) declined to approve its diabetes candidates, Tresiba
(insulin degludec) and Ryzodeg (insulin degludec/insulin aspart), on the basis
of the submitted data.

The FDA issued a complete response letter (CRL) asking Novo Nordisk to conduct
a dedicated cardiovascular outcomes study and provide additional
cardiovascular data.

Moreover, the FDA said that it will not grant approval to these candidates
until the company resolves the issues mentioned in a warning letter given by
the FDA in Dec 2012. The warning letter specified violations of current good
manufacturing practice (CGMP) regulations for finished pharmaceuticals at the
company's Novo Alle, Bagsvaerd Denmark facility.

Meanwhile, we note that both Tresiba and Ryzodeg are approved in Japan , the
EU and Mexico . In the EU, Novo Nordisk is planning to launch Tresiba first
and Ryzodeg a year later. Tresiba and Ryzodeg will be available in Novo
Nordisk's latest prefilled insulin pen named FlexTouch in Europe . Tresiba
will initially be launched in the UK and Denmark in the first half of 2013 and
in other European markets throughout 2013 and 2014.

Our Take

We are discouraged by the CRL issued by the FDA. Considering Novo Nordisk's
statement that it will not be in a position to provide the required data in
2013, we expect a significant delay in the US approval of Tresiba and Ryzodeg.
The US approval of Tresiba and Ryzodeg would have strengthened Novo Nordisk's
diabetes franchise. We expect shares to react negatively to the news.

Novo Nordisk currently carries a Zacks Rank #1 (Strong Buy). Other large-cap
pharma companies Sanofi (NYSE:SNY) and Bayer AG (OTC:BAYRY) both have Zacks
Rank #2 (Buy) ratings.

Get the full analysis of all these stocks by going to

About the Bull and Bear of the Day

Every day, the analysts at Zacks Equity Research select two stocks that are
likely to outperform (Bull) or underperform (Bear) the markets over the next
3-6 months.

About the Analyst Blog

Updated throughout every trading day, the Analyst Blog provides analysis from
Zacks Equity Research about the latest news and events impacting stocks and
the financial markets.

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative
analysis to help investors know what stocks to buy and which to sell for the

Continuous analyst coverage is provided for a universe of 1,150 publicly
traded stocks. Our analysts are organized by industry which gives them keen
insights to developments that affect company profits and stock performance.
Recommendations and target prices are six-month time horizons.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the
latest analysis from Zacks Equity Research. Subscribe to this free newsletter
today by visiting

About Zacks is a property of Zacks Investment Research, Inc., which was formed
in 1978 by Leonard Zacks. As a PhD from MIT Len knew he could find patterns in
stock market data that would lead to superior investment results. Amongst his
many accomplishments was the formation of his proprietary stock picking
system; the Zacks Rank, which continues to outperform the market by nearly a 3
to 1 margin. The best way to unlock the profitable stock recommendations and
market insights of Zacks Investment

Research is through our free daily email newsletter; Profit from the Pros. In
short, it's your steady flow of Profitable ideas GUARANTEED to be worth your
time! Register for your free subscription to Profit from the Pros at

Visit for information about the performance
numbers displayed in this press release.

Follow us on Twitter:

Join us on Facebook:

Disclaimer: Past performance does not guarantee future results. Investors
should always research companies and securities before making any investments.
Nothing herein should be construed as an offer or solicitation to buy or sell
any security.

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339

SOURCE Zacks Investment Research, Inc.

Press spacebar to pause and continue. Press esc to stop.